NRAS and melanoma: Building on the findings shown in Fig. 1a, b, which indicated that NRAS-mRNA expression may be a specific vulnerability of NRAS-mutant melanoma cells, we applied the treatment to three normal, non-cancerous cell lines, and a BRAFV600E-mutant melanoma cell line, to evaluate whether NRAS-ASOs provoked toxic side effects in NRAS-WT cell lines.